Sandy Gould, Ph.D.

Sandy Gould is the director of medicinal chemistry for the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. Her group focuses on designing and implementing strategies for the development of novel therapeutics for cancer, psychiatric disorders, inflammatory and metabolic disorders, and rare diseases.

Prior to joining the Broad, Gould was a senior director of project management at NextRNA Therapeutics, where she managed two drug discovery projects and coordinated collaborations with biology, biochemistry, and chemistry contract research organizations, as well as academic experts and small biotechnology companies, to support research progress. Prior to that, she spent 23 years at Takeda Pharmaceuticals (formerly Millennium Pharmaceuticals, Inc.), where she played a variety of roles including associate director of oncology and medicinal chemistry, and the director of scientific affairs in research strategy and operations within the oncology division. At Takeda, Gould managed academic collaborations, a group responsible for the creation and review of non-clinical pharmacology reports for agency filings, and multiple chemistry project teams. She contributed to several oncology and immuno-oncology projects, developed and managed intellectual property strategy across the company’s Cambridge-based chemistry department, and led an industry/NGO/academic collaboration focused on identifying and developing anti-malaria drugs with novel mechanisms of action.

Gould earned a B.A. from the University of Pennsylvania and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology. She completed postdoctoral training at Harvard University.